Bionano Genomics, Inc

www.bionanogenomics.com

At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

news image

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More

IMMUNOSCAPE INTENSELY ENGAGED IN IMMUNOLOGY BREAKTHROUGHS FOR COVID-19 RAISED $11M IN A GLOBAL EQUITY FINANCING

ImmunoScape | August 13, 2020

news image

ImmunoScape (www.ImmunoScape.com), a biotech firm enabling unprecedented insights into the human immune system, today announced that it has raised USD $11 million (SGD $14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already inte...

Read More

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ENTERS STRATEGIC PARTNERSHIP WITH OXGENE™ TO ADDRESS SUPPLY BOTTLENECKS IN GENE THERAPY DEVELOPMENT & MANUFACTURING

FUJIFILM Diosynth Biotechnologies | April 23, 2020

news image

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies. This partnership will enable FDB to deliver gene therapy products to clients with an approximate 25% le...

Read More

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

news image

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More
news image

INDUSTRIAL IMPACT

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More
news image

IMMUNOSCAPE INTENSELY ENGAGED IN IMMUNOLOGY BREAKTHROUGHS FOR COVID-19 RAISED $11M IN A GLOBAL EQUITY FINANCING

ImmunoScape | August 13, 2020

ImmunoScape (www.ImmunoScape.com), a biotech firm enabling unprecedented insights into the human immune system, today announced that it has raised USD $11 million (SGD $14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already inte...

Read More
news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES ENTERS STRATEGIC PARTNERSHIP WITH OXGENE™ TO ADDRESS SUPPLY BOTTLENECKS IN GENE THERAPY DEVELOPMENT & MANUFACTURING

FUJIFILM Diosynth Biotechnologies | April 23, 2020

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies. This partnership will enable FDB to deliver gene therapy products to clients with an approximate 25% le...

Read More
news image

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us